GC-REAAD™ ITIH3 ELISA Assay Kit

$890.00

GC-REAAD™ ITIH3 ELISA Test (Gastric Carcinoma – Recombinant Antigen-Antibody Detection) is intended for qualitative and semi-quantitative detection of human Inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3) proteins in human plasma/serum. The test utilises sandwich ELISA using two layers of antibodies (i.e. capture and detection antibody) to determine a patient’s ITIH3 proteins levels in plasma/serum samples which aid in the diagnosis of Gastric Cancer.

GC-REAAD™ ITIH3 ELISA Assay Kit

For Research Use Only

Size: 1×96 wells
Sensitivity: 0.4 RU
Standard Range: 0.4-0.7 RU
Incubation Time: 1.25 hours
Sample Type: Serum, plasma
Sample Size: 100 µl

Controls Included

Product manufactured by Restalyst.

Additional Information

Assay Background


Gastric Carcinoma (GC) is the fifth most common cancer malignancy in the world with more than 70% of cases occur in developing countries, and half the world total occurs in Eastern Asia [3,5,6]. GC is the third leading cause of cancer death worldwide. The highest estimated mortality rates are in Eastern Asia. High mortality rates are also present in Central and Eastern Europe, and in Central and South America. The level of ITIH3 proteins has been found to be closely associated with Gastric Carcinoma. Higher levels of ITIH3 proteins were detected in plasma of patients with gastric carcinoma (both early and late) as compared to plasma of non-carcinoma patients [1,2,4].
GC-REAAD™ sandwich ELISA uses two layers of antibodies (i.e. capture and detection antibody) targeting at two different antigenic epitopes expressed by human ITIH3 proteins capable of binding to the respective antibody to semi-quantify the level of human ITIH3 protein. The test uses an arbitrary unit of measurement known as REAAD™-units (RU) which is used for determining the patients’ GC risk level.
GC-REAAD™ is useful for the semi-quantification of human ITIH3 proteins in patients. All data from these assays, however at best offer supplementary information to clinicians and act as an aid to diagnosis only. It is therefore important that a diagnosis is made in conjunction with other recommended clinical investigations.

Assay Principle


Human ITIH3 Capture Antibody is first coated onto the wells of microplates. Samples, standards and controls containing ITIH3 proteins are pipetted into these wells. During the first incubation, the protein antigen binds to the capture antibody and form antigen-antibody complexes. After washing, Human ITIH3 Detection Antibody is added to the wells and binds to the immobilised protein captured during the first incubation. After removal of excess detection antibody, a Horseradish Peroxidase (HRP) conjugate antibody is added and binds to the detection antibody. After a third incubation and washing to remove the excess HRP conjugate, a TMB substrate solution (tetramethylbenzidine) is added and is converted by the enzyme to a detectable form (color signal). The enzymatic reaction will then be stopped by the addition of 1N Sulphuric acid, which will turn the blue coloration to yellow. The microwells can be read on any suitable spectrophotometer or microwell ELISA plate reader. It is always recommended to read the wells at 450 nm against a 620-630 nm reference filter to eliminate any possible causes of interference. The intensity of this colored product is directly proportional to the concentration of antigen present in the original specimen.

Manual

Product Manual